InvestSMART

Orthocell Limited (ASX:OCC)

ALERT: Price-sensitive ASX Announcement for OCC
Current share price for OCC : $0.720 -0.16 (-18.18%)+
Announcement
Release
30 Apr 2026 9:14AM
Price at Release
$0.880
Full Release
download
Summary
Orthocell Limited has achieved its first commercial sales of the nerve repair device Remplir in the Canadian market, marking a significant milestone in its global commercialization strategy. Following regulatory approval from Health Canada in the second half of 2025, the company has successfully launched Remplir across Canada, leveraging a distributor-led model to gain market entry. This approach has proven capital-efficient and has enabled Orthocell to establish significant national coverage. The Canadian market, valued at approximately US$75 million, is part of Orthocell's broader strategy which includes expansion plans into other key markets such as the EU/UK. The company remains financially robust with over A$48 million in cash and no debt, ensuring continued support for its commercial expansion efforts.
Key Points
  • First commercial sales of Remplir in Canada.
  • Regulatory approval from Health Canada achieved in 2H CY25.
  • Distributor-led model facilitates market entry.
  • Remplir sales mark a milestone in global rollout.
  • Significant national coverage established in Canada.
  • Expansion plans include EU/UK market.
  • Company well-funded with A$48 million in cash.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.